CTLA4 and lymphedema: A further extension of the course of the disease in the preclinical model would not assist the answer of our clinical question either, as the scope of the experiment was not the treatment of advanced lymphedema but to replicate the conditions to assess the protective effect of anti-CTLA4 against lymphedema onset, which was faithfully conducted with the applied setup.